Certain clinical trials of ruboxistaurin (RBX), a PKCβ inhibitor, in the treatment of diabetic complications revealed that inhibition of PKCβ significantly reduces diabetic retinopathy, nephropathy, and neuropathy (Geraldes and King, 2010; Mochly-Rosen et al., 2012). This evidence concerns the gene PRKCB and neuropathy.